Laigo Bio

Executive Summary

Laigo Bio, founded in 2019 and headquartered in Leiden, Netherlands, is a private biotechnology company at the forefront of protein degradation for targeted therapies. The company leverages innovative approaches such as PROTACs and molecular glues to eliminate disease-causing proteins that have historically been undruggable with conventional modalities. By focusing on protein degradation, Laigo Bio aims to address a broad range of therapeutic areas, including oncology and beyond, offering new hope for patients with conditions that have limited treatment options. Despite being early-stage with no disclosed pipeline or funding details, the company's strategic location in the vibrant Leiden biotech cluster provides access to top talent and collaborative opportunities. With a strong scientific foundation and a clear focus on a cutting-edge modality, Laigo Bio is well-positioned to make significant contributions to the protein degradation field. Laigo Bio's potential is underscored by the growing interest in targeted protein degradation as a transformative therapeutic strategy. The company's ability to advance its platform and progress toward clinical development will be key to its success. While specific milestones are not publicly available, typical catalysts for a company at this stage include securing series A or B financing, forming strategic partnerships with larger pharmaceutical companies, and advancing lead programs toward investigational new drug (IND) enabling studies. The company's conviction score reflects its promising yet early-stage profile, with a moderate-to-high potential contingent on execution and market conditions.

Upcoming Catalysts (preview)

• Q4 2026Series A or B Financing Round70% success
• Q1 2027Strategic Partnership with Pharma for Protein Degradation Platform60% success
• Q2 2027Lead Program IND Filing or First-in-Human Trial Initiation50% success